References
- Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biol Targets Ther. 2014;8:67–81.
- Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: the Northern California epidemiology of uveitis study. Ophthalmology. 2004;111(3):491–500. doi:https://doi.org/10.1016/j.ophtha.2003.06.014.
- Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16. doi:https://doi.org/10.1080/09273948.2016.1196713.
- Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23(5):705–717. doi:https://doi.org/10.5301/ejo.5000278.
- INE. Proyección de la Población de España 2014–2064: notas de prensa. Instituto Nacional de Estadística. 2014:1–9.
- Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine. 2006;33(4):231–237. doi:https://doi.org/10.1016/j.cyto.2005.12.012.
- https://www.ema.europa.eu/en/medicines/human/EPAR/humira.
- Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–796.e3. doi:https://doi.org/10.1016/j.ophtha.2013.09.048.
- Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:https://doi.org/10.1056/NEJMoa1509852.
- Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi:https://doi.org/10.1016/S0140-6736(16)31339-3.
- Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–1087. doi:https://doi.org/10.1016/j.ophtha.2017.12.039.
- Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One. 2012;7:3. doi:https://doi.org/10.1371/journal.pone.0033559.
- Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516.
- Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:https://doi.org/10.1016/S0161-6420(85)34001-0.
- Karube H, Kamoi K, Ohno-Matsui K. Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet’s disease. Int Med Case Rep J. 2016;9:301–304. doi:https://doi.org/10.2147/IMCRJ.S117731.
- Chang JHM, Wakefield D. Uveitis: a global perspective. Ocul Immunol Inflamm. 2002;10(4):263–279. doi:https://doi.org/10.1076/ocii.10.4.263.15592.
- Pathanapitoon K, Dodds EM, Cunningham ET, Rothova A. Clinical spectrum of HLA-B27-associated ocular inflammation. Ocul Immunol Inflamm. 2017;25(4):569–576. doi:https://doi.org/10.1080/09273948.2016.1185527.
- Rothova A, Van Veenendaal WG, Linssen A. Clinical features of acute anterior uveitis. Am J Ophthalmol. 1987;103(2):137–145. doi:https://doi.org/10.1016/S0002-9394(14)74218-7.
- Power WJ, Rodriguez A, Pedroza-Seres M, Foster CS. Outcomes in anterior uveitis associated with the HLA-B27 haplotype. Ophthalmology. 1998. doi:https://doi.org/10.1016/S0161-6420(98)99033-9.
- Matas J, Llorenç V, Fonollosa A, et al. Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis. PLoS One. 2019;14(1):1. doi:https://doi.org/10.1371/journal.pone.0210799.
- Radovits BJ, Kievit W, Fransen J, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68(9):1470–1473. doi:https://doi.org/10.1136/ard.2008.094730.
- Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):30–35. doi:https://doi.org/10.1016/j.cgh.2010.09.026.
- Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42(4):441–451. doi:https://doi.org/10.1111/apt.13294.
- Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of adalimumab therapy in refractory uveitis due to behçet’s disease. Ophthalmology. 2018;125(9):1444–1451. doi:https://doi.org/10.1016/j.ophtha.2018.02.020.
- Jani M, Barton A, Warren RB, Griffiths CEM, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatol (United Kingdom). 2014;53:213–222.
- Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies. Ophthalmology. 2016;123(12):2618–2625. doi:https://doi.org/10.1016/j.ophtha.2016.08.025.
- Lahaye C, Tatar Z, Dubost JJ, Soubrier M. Overview of biologic treatments in the elderly. Jt Bone Spine. 2015;82(3):154–160. doi:https://doi.org/10.1016/j.jbspin.2014.10.012.
- Soubrier M, Mathieu S, Payet S, Dubost JJ, Ristori JM. Elderly-onset rheumatoid arthritis. Jt Bone Spine. 2010;77(4):290–296. doi:https://doi.org/10.1016/j.jbspin.2010.04.004.
- Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;48:35–45.
- Van De Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516. doi:https://doi.org/10.1136/ard.2003.013052.
- Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45. doi:https://doi.org/10.1002/art.10697.
- Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006. doi:https://doi.org/10.1136/ard.2005.044404.
- Filippini M, Bazzani C, Favalli EG, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38(2–3):90–96. doi:https://doi.org/10.1007/s12016-009-8142-1.
- Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford). 2011;50(8):1431–1439. doi:https://doi.org/10.1093/rheumatology/ker113.
- Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C. Tolerance and effectiveness of anti-tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Care Res. 2007;57(4):679–685. doi:https://doi.org/10.1002/art.22688.
- Askling J, Van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009;60(11):3180–3189. doi:https://doi.org/10.1002/art.24941.
- Momose M, Asahina A, Hayashi M, Yanaba K, Umezawa Y, Nakagawa H. Biologic treatments for elderly patients with psoriasis. J Dermatol. 2017;44(9):1020–1023. doi:https://doi.org/10.1111/1346-8138.13853.
- Pawelec G. Immunosenescence and cancer. Biogerontology. 2017;18(4):717–721. doi:https://doi.org/10.1007/s10522-017-9682-z.